Logo
x

Search

Subscribe Now

plans

Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted COVID-19 Vaccine Candidate

Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted COVID-19 Vaccine Candidate

  • February 2, 2021
Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

  • August 24, 2020
Celltrion Plans to Initiate P-I Trial for its CT-P41 (biosimilar- denosumab) in September 2020

Celltrion Plans to Initiate P-I Trial for its CT-P41 (biosimilar- denosumab) in September 2020

  • August 14, 2020
Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India

Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India

  • May 22, 2020
Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia

Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia

  • April 29, 2020
Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation

Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation

  • February 10, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.